Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers

pubmed: wnt1 2023-01-28

Summary:

HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15-20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50% of the patients respond poorly to trastuzumab, illustrating that novel therapy is warranted to overcome the resistance. We previously reported that in the majority of HER2+ breast-cancer patients,...

Link:

https://pubmed.ncbi.nlm.nih.gov/36145262/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=16uwQpOeqFYN8R4TKOtwPy2utpqy9ex2oldalD2yF_fQHv2caq&fc=None&ff=20230128214236&v=2.17.9.post6+86293ac

From feeds:

Exome ยป pubmed: wnt1

Tags:

Authors:

Ratnakar Reddy Kuchukulla, Injeoung Hwang, Sang Won Park, Sojeong Moon, Suhn Hyung Kim, Sumin Kim, Hwan Won Chung, Mi-Jung Ji, Hyun-Mee Park, Gu Kong, Wooyoung Hur

Date tagged:

01/28/2023, 21:42

Date published:

09/23/2022, 06:00